Thereby, targeting the innate response with RIG-I agonists is a potential strategy to trigger de novo inflammation, Ag-specific DCs cross-presentation, and T-cell cross-priming, and to heightened ICIs sensitivity in tumours, especially in non-T-cell-inflamed types. This evidence concerns the gene RIGI and neoplasm.